WCLC 2025 - Posters & ePosters-EP.13.22 Survival and Treatment Patterns in Limited Disease-SCLC: Real World Data From the Swedish National Lung Cancer Registry

EP.13.22 Survival and Treatment Patterns in Limited Disease-SCLC: Real World Data From the Swedish National Lung Cancer Registry

Back to course

Pdf Summary

This retrospective observational study analyzed real-world data from the Swedish National Lung Cancer Registry to evaluate survival and treatment patterns in 1,046 patients diagnosed with limited disease small cell lung cancer (LD-SCLC) from 2014 to 2023, prior to immunotherapy approval. LD-SCLC accounted for about 14-21% of lung cancers, with most cases (over 80%) in stage III, and a median age of 71 years. The majority had favorable performance status (PS 0-1).<br /><br />Treatment approaches included curative-intent chemoradiotherapy (CRT), either concomitant (cCRT) or sequential (sCRT), and systemic therapies such as chemotherapy alone or combined with immunotherapy. CRT was administered to 41% of patients, while about 40% received systemic therapy only.<br /><br />Patients treated with CRT demonstrated substantially better outcomes compared to those receiving systemic therapy alone, correlating with better baseline health characteristics. Median progression-free survival (PFS) in the CRT group was 15.4 months, versus 7.0 months in the systemic therapy group; median overall survival (OS) was 27.2 months versus 11.0 months, respectively. Among CRT patients, those who received prophylactic cranial irradiation (PCI) showed even further improved survival, with median OS of 32.4 months compared to 23.8 months without PCI.<br /><br />The survival outcomes of CRT-treated patients aligned closely with results from previous phase 3 clinical trials such as the CONVERT study. The findings support CRT with PCI as the standard of care in LD-SCLC and highlight the potential survival benefit of PCI in reducing brain metastases. The role of PCI following CRT merits further research, especially with emerging immunotherapy options.<br /><br />In summary, this Swedish nationwide real-world data confirms that CRT remains the primary curative treatment for LD-SCLC, and the addition of PCI after CRT enhances survival outcomes.

Asset Subtitle

Johan Isaksson

Meta Tag

Speaker Johan Isaksson

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

limited disease small cell lung cancer

LD-SCLC

curative-intent chemoradiotherapy

concomitant chemoradiotherapy

sequential chemoradiotherapy

systemic therapy

prophylactic cranial irradiation

progression-free survival

overall survival

Swedish National Lung Cancer Registry